Lindsey Rolfe

Dr. Lindsey Rolfe is the EVP of Clinical Development and Pharmacovigilance & Chief Medical Officer at Clovis Oncology. Lindsey has over 25 years of experience in the pharmaceutical and biotech industry.

Lindsey started their career as a project manager at Covance in 2000, where they managed early phase oncology trials. In 2004, they moved to Fresenius Biotech as an associate director of clinical development, overseeing clinical operations for phase I-III oncology trials.

In 2010, Dr. Rolfe joined MedImmune as a senior clinical program manager for oncology. There they managed global clinical development programs across multiple therapeutic areas. In 2012, they took a position as an associate director of clinical operations at Ziopharm Oncology, where they oversaw clinical trial operations for phase I-III oncology trials.

In 2014, Dr. Rolfe joined Kadmon Pharmaceuticals as an associate director of clinical operations. Lindsey oversaw all aspects of clinical trial operations for phase I-III trials across multiple therapeutic areas. In 2015, they joined Takeda Oncology as an associate director of clinical science, overseeing all aspects of clinical development for oncology drugs in development.

Dr. Rolfe has a wealth of experience in the pharmaceutical and biotech industry, and has played a key role in the development of many oncology drugs that are now on the market.

Lindsey Rolfe has a BS in Zoology, Anatomy, Spanish from Brigham Young University and is currently studying cell biology and immunology at the University of Kentucky.

They work with Daniel W. Muehl - EVP & CFO, Ann Bozeman - EVP, Human Resources, and Thomas Fuglsang Harding - EVP & Chief Scientific Officer. Lindsey Rolfe reports to Patrick J. Mahaffy, President & CEO.